ВОПРОСЫ ТЕРАПИИ ИНТЕРСТИЦИАЛЬНОГО ПОРАЖЕНИЯ ЛЕГКИХ ПРИ НЕКОТОРЫХ СИСТЕМНЫХ АУТОИММУННЫХ ЗАБОЛЕВАНИЯХ


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

К системным аутоиммунным заболеваниям (САЗ) относится разнородная группа иммунологически опосредованных воспалительных заболеваний, для которых характерно развитие полиорганной недостаточности. У больных САЗ может наблюдаться интерстициальное поражение легких (ИПЛ). Ведущую роль в диагностике ИПЛ играет компьютерная томография высокого разрешения легких и исследование функции внешнего дыхания. Несмотря на достигнутые успехи в решении вопросов патогенеза, диагностики ИПЛ при САЗ, на сегодняшний день не существует эффективной иммуномодулирующей терапии ИПЛ-САЗ. Проводимая терапия ИПЛ нацелена на подавление иммуновоспалительного процесса. В статье обсуждается эффективность проводимой иммуносупрессивной терапии при некоторых САЗ.

Полный текст

Доступ закрыт

Об авторах

Д. В Бестаев

ФГБУ «НИИР им. В.А. Насоновой» РАМН, Москва

Email: davidbestaev@rambler.ru
научный сотрудник

Е. Л Насонов

ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова» Минздрава России, Москва; ФГБУ «НИИР им. В.А. Насоновой» РАМН

д.м.н., проф., акад. РАН, зав. кафедрой ревматологии ФППОВ; директор

Список литературы

  1. Castelino F.V., Goldberg H., Dellaripa P.F. American College of Rheumatology Annual Meeting. San Francisco, CA; 2008. The impact of rheumatologic evaluation on the management of patients with interstitial lung disease (ILD) [abstract 637].
  2. Steen V.D., Lanz J.K. Jr., Conte C., et al. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum. 1994; 37: 1290-96.
  3. Akesson A., Scheja A., Lundin A., Wollheim F.A. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum. 1994; 37: 729-35.
  4. White B., Moore W.C., Wigley F.M., et.al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern. Med. 2000; 132: 947-54.
  5. Tashkin D.P., Elashoff R., Clements P.J., et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am. J. Respir. Crit. Care Med.2007; 176: 1026-34.
  6. Hoyles R.K., Ellis R.W., Wellsbury J., et al. A multicenter, prospective, randomized, doubleblind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006; 54: 3962-70.
  7. Zamora A.C., Wolters P.J., Collard H.R., et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med. 2008; 102: 150-55.
  8. Gerbino A.J., Goss C.H., Molitor J.A. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest. 2008; 133: 455-60.
  9. Dheda K., Lalloo U.G., Cassim B, Mody G.M. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin. Rheumatol. 2004; 23: 306-09.
  10. Berezne A., Ranque B., Valeyre D., et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J. Rheumatol. 2008; 35: 1064-72.
  11. Silver R.M., et al. Endothelin and scleroderma lung disease. Rheumatology (Oxford). 2008; 47(Suppl 5): v25-v26.
  12. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.2008; 177: 75-81.
  13. An Of cial ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am. J. Respir. Crit. Care Med. 2011; 183: 788-824.
  14. Nagai S., Hamada K., Shigematsu M., et al. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern. Med. 2002; 41: 1118-23.
  15. Schachna L., Medsger T.A. Jr., Dauber J.H., et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum. 2006; 54: 3954-61.
  16. Massad M.G., Powell C.R., Kpodonu J., et al. Outcomes of lung transplantation in patients with scleroderma. World J. Surg. 2005; 29: 1510-15.
  17. Bouros D., Wells A.U., Nicholson A.G., et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am. J. Respir. Crit. Care Med. 2002; 165: 1581-86.
  18. Wells A.U., Cullinan P., Hansell D.M., et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am. J. Respir. Crit. Care Med. 1994; 149: 1583-90.
  19. Daniels C.E., Lasky J.A., Limper A.H., et al. Imatinib treatment for IPF: randomized placebo controlled trial results. Am. J. Respir. Crit. Care Med. 2009; 181: 604-10.
  20. Van Daele P.l., Dik W.A., Thio H.B., et al. Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum. 2008; 58: 2549-52.
  21. Sfikakis P.P., Gorgoulis V.G., Katsiari C.G., et al. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford). 2008; 47: 735-37.
  22. McDonagh J., Greaves M., Wright A.R., et al. High resolution computed tomography of the lungs in patients with rheumatoid arthritis and interstitial lung disease. Br. J. Rheumatol. 1994; 33: 118-22.
  23. Lee H.K., Kim D.S., Yoo B., et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005; 127: 2019-27.
  24. Turesson C., Matteson E.L., Colby T.V., et al. Increased CD4+T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis. Arthritis Rheum. 2005; 52: 73-79.
  25. Lynch J.P., Saggar R., Weigt S.S., et al. Usual interstitial pneumonia. Semin Respir. Crit. Care Med.2006; 27: 634-651.
  26. Demedts M., Behr J., Buhl R., et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353: 2229-42.
  27. Saketkoo L.A., Espinoza L.R. Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug. Arch Intern. Med. 2008; 168: 1718-19.
  28. Chen I.J., Jan Wu Y.J., Lin C.W., et al. Interstitial lung disease in polymyositis and dermatomyositis. Clin. Rheumatol. 2009; 28: 639-646.
  29. Hayashi S., Tanaka M., Kobayashi H., et al. High-resolution computed tomography characterization of interstitial lung diseases in polymyositis/dermatomyositis. J. Rheumatol. 2008; 35: 260-69.
  30. Tillie-Leblond I., Wislez M., Valeyre D., et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax. 2008; 63: 53-59.
  31. Kubo M., Ihn H., Yamane K., et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology (Oxford). 2000; 39: 632-36.
  32. Fujisawa T., Suda T., Nakamura Y., et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol. 2005; 32: 58-64.
  33. Yamasaki Y., Yamada H., Yamasaki M., et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford). 2007; 46: 124-30.
  34. Ochi S., Nanki T., Takada K., et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin. Exp. Rheumatol. 2005; 23: 707-10.
  35. Wilkes M.R., Sereika S.M., Fertig N., et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005; 52: 2439-46.
  36. Sem M., Molberg O., Lund M.B., Gran J.T. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford). 2009; 48: 968-71.
  37. Rios Fernandez R., Callejas Rubio J.L., Sanchez Cano D., et al. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin. Exp. Rheumatol. 2009; 27: 1009-16.
  38. Ito I., Nagai S., Kitaichi M., Nicholson A.G., et al. Pulmonary manifestations of primary Sjogren's syndrome: a clinical, radiologic, and pathologic study. Am. J. Respir. Crit. Care Med. 2005; 171: 632-38.
  39. Parambil J.G., Myers J.L., Lindell R.M., et al. Interstitial lung disease in primary Sjogren syndrome. Chest.2006; 130: 1489-95. doi: 10.1378/chest.130.5.1489.
  40. Pego-Reigosa J.M., Medeiros D.A., Isenberg D.A. Respiratory manifestations of systemic lupus erythematosus: old and new concepts. Best Pract. Res. Clin. Rheumatol. 2009; 23: 469-80.
  41. Lim S.W., Gillis D., Smith W., et al. Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports. Intern. Med J. 2006; 36: 260-62.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2014